A Phase 3 interventional study of Triptorelin Pamoate in Central Precocious Puberty, sponsored by Ipsen. Completed at 14 sites in China. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Puberty, Precocious with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Puberty, Precocious · China.
Among the 17 studies in Puberty, Precocious with a site in China, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 9th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →4 of the 17 studies in Puberty, Precocious with a site in China are open now. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 4–9 · Women only
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 6–12
Children's Hospital of Fudan University · Sites in China
Ages 5–9 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 2–10
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: Up to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2021.
This study's enrollment of 66 is close to the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 94 across the 13 interventional studies, 835 across the 4 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 7 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 4 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
2 of the studies in Puberty, Precocious with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06510764Phase 3Children's Hospital of Fudan UniversityA Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty | 2027-07-01 |
| NCT06487143Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEfficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Puberty, Precocious with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the protocol is to assess the efficacy of the triptorelin 6 month PR (Prolonged Release) formulation in suppressing LH (Luteinising hormone) levels to prepubertal levels (defined as a peak LH ≤5 IU/L) after i.v. GnRH (Gonadotropin-releasing Hormone) stimulation at Month 6 (Day 169) in Chinese children with CPP (Central Precocious Puberty).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Triptorelin Pamoate
Triptorelin 6-month formulation for IM on day 1 and Month 6.
Percentage of Participants With Luteinising Hormone (LH) Suppression
LH response was defined as a peak LH \<=5 international units per liter (IU/L) after intravenous (IV) gonadotropin-releasing hormone (GnRH) stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: At Month 6
Percentage of Participants With LH Response to GnRH Test
LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: At Months 3 and 12
Change From Baseline in Basal Serum LH and Follicle-Stimulating Hormone (FSH) Levels
Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
Time frame: Baseline and at Months 3, 6, 9 and 12
Change From Baseline in Peak Serum LH and FSH Level After the GnRH Stimulation Test
Peak LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak serum LH \<=5 IU/L among the four timepoints (T0, T30, T60 and T90). The FSH response to GnRH stimulation was the peak serum FSH level among the four timepoints (T0, T30, T60 and T90).
Time frame: Baseline and at Months 3, 6 and 12
Percentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 12
Peak LH serum concentration was analyzed centrally. LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of peak LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: Month 6 to Month 12
Percentage of Participants With Prepubertal Levels of Sex Steroids
Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol \<=20 picogram (pg)/ milliliter (mL) in female participants and testosterone \<=30 nanogram (ng)/ deciliter (dL) in male participants. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: At Months 3, 6, 9 and 12
Change From Baseline in Mean Height for Age (Z-Score)
Z-scores are calculated using Centers for Disease Control and Prevention (CDC) Growth Charts. Change from baseline was defined as the values for Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to study treatment administration. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
Time frame: Baseline and at Months 6 and 12
Change From Baseline in Percentile for Height for Age
Z-scores were calculated using CDC growth charts, that contained Box-Cox transformation (L), the median (M) and the generalized coefficient of variation (S). Percentile was obtained using the following equation M (1 + LSZ) \*\* (1/L), where \*\* indicated an exponent, such that m (1+LSZ)\*\* (1/L) meant raising (1+LSZ) to the (1/L)th power and then multiplying the M. Z was the Z-score that corresponds to the percentile. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline was defined as the values for percentile of Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
Time frame: Baseline and at Months 6 and 12
Change From Baseline in Growth Velocity
Growth velocity analysis was part of auxological parameter. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
Time frame: Baseline and at Months 6 and 12
Percentage of Participants With Bone Age (BA)/Chronological Age (CA) Ratio Not Risen
BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Percentage of response was calculated as n/N\*100, where n was number of participants in the specified category and N was number of participants in the analysis population.
Time frame: At Months 6 and 12
Change From Baseline in BA:CA Ratio
BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Change from baseline was defined as the values for BA:CA ratio at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
Time frame: Baseline, Months 6 and 12
Percentage of Participants With Stabilized Pubertal Stage
Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital development stage (GDS) in male participants, breast development stage (BDS) in female participants and pubic hair development (PHD) stage in both sexes. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: At Months 6 and 12
Percentage of Participants With Regression of Uterine Length
Uterine length was determined by transabdominal ultrasound. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: At Months 6 and 12
Percentage of Participants With Absence of Progression of Testis Volumes
Testis volume was a clinical assessment with orchidometer. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
Time frame: At Months 6 and 12
Change From Baseline in Body Mass Index (BMI)
BMI analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
Time frame: Baseline and at Months 6 and 12
Change From Baseline in Weight
Weight analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
Time frame: Baseline and at Months 6 and 12
Plasma Concentrations of Triptorelin
Blood samples were collected at specified timepoints.
Time frame: Day 1, 4 hours post-injection; Month 3; Month 6, predose; Month 6, 4 hours post-injection; and Month 12
This Phase 3, open-label, single arm, study was conducted in children with central precocious puberty (CPP) at 12 investigational sites in China from 25 August 2021 to 13 February 2023.
| Milestone | All Participants |
|---|---|
| Started | 66 |
| Completed | 65 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
LH response was defined as a peak LH \<=5 international units per liter (IU/L) after intravenous (IV) gonadotropin-releasing hormone (GnRH) stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Luteinising Hormone (LH) Suppression | 100 (94.6 to 100.0) |
LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| Month 3 | 97.0 (89.5 to 99.6) |
| Month 12 | 98.5 (91.8 to 100.0) |
Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
| IU/L | All Participants |
|---|---|
| LH, Month 3 | -1.6420 ± 2.4287 |
| LH, Month 6 | -1.8015 ± 2.4109 |
| LH, Month 9 | -1.6307 ± 2.3396 |
| LH, Month 12 | -1.8504 ± 2.4524 |
| FSH, Month 3 | -2.9938 ± 1.9450 |
| FSH, Month 6 | -2.4871 ± 2.0414 |
| FSH, Month 9 | -2.8586 ± 1.9310 |
| FSH, Month 12 | -2.5348 ± 1.9162 |
Peak LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak serum LH \<=5 IU/L among the four timepoints (T0, T30, T60 and T90). The FSH response to GnRH stimulation was the peak serum FSH level among the four timepoints (T0, T30, T60 and T90).
| IU/L | All Participants |
|---|---|
| LH, Month 3 | -26.0075 ± 19.8863 |
| LH, Month 6 | -26.2867 ± 20.3004 |
| LH, Month 12 | -26.6065 ± 20.5680 |
| FSH, Month 3 | -11.7297 ± 5.1787 |
| FSH, Month 6 | -10.0656 ± 5.0160 |
| FSH, Month 12 | -10.1645 ± 5.2442 |
Peak LH serum concentration was analyzed centrally. LH response was defined as a peak LH \<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of peak LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| Percentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 12 | 98.5 (91.8 to 100.0) |
Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol \<=20 picogram (pg)/ milliliter (mL) in female participants and testosterone \<=30 nanogram (ng)/ deciliter (dL) in male participants. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| Month 3 | 97.0 (89.5 to 99.6) |
| Month 6 | 100 (94.6 to 100.0) |
| Month 9 | 86.4 (75.7 to 93.6) |
| Month 12 | 98.5 (91.8 to 100.0) |
Z-scores are calculated using Centers for Disease Control and Prevention (CDC) Growth Charts. Change from baseline was defined as the values for Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to study treatment administration. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
| Z-score | All Participants |
|---|---|
| Month 6 | 0.0734 ± 0.1433 |
| Month 12 | 0.0204 ± 0.1567 |
Z-scores were calculated using CDC growth charts, that contained Box-Cox transformation (L), the median (M) and the generalized coefficient of variation (S). Percentile was obtained using the following equation M (1 + LSZ) \*\* (1/L), where \*\* indicated an exponent, such that m (1+LSZ)\*\* (1/L) meant raising (1+LSZ) to the (1/L)th power and then multiplying the M. Z was the Z-score that corresponds to the percentile. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline was defined as the values for percentile of Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
| percentiles of Z-score | All Participants |
|---|---|
| Month 6 | 1.4675 ± 2.8638 |
| Month 12 | 0.2810 ± 3.2237 |
Growth velocity analysis was part of auxological parameter. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
| centimeter (cm)/year | All Participants |
|---|---|
| Month 6 | -3.938 ± 6.075 |
| Month 12 | -4.798 ± 5.577 |
BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Percentage of response was calculated as n/N\*100, where n was number of participants in the specified category and N was number of participants in the analysis population.
| percentage of participants | All Participants |
|---|---|
| Month 6 | 95.5 (87.3 to 99.1) |
| Month 12 | 92.4 (83.2 to 97.5) |
BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Change from baseline was defined as the values for BA:CA ratio at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
| ratio | All Participants |
|---|---|
| Month 6 | -0.04 ± 0.06 |
| Month 12 | -0.06 ± 0.07 |
Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital development stage (GDS) in male participants, breast development stage (BDS) in female participants and pubic hair development (PHD) stage in both sexes. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| BDS for female participants, Month 6 | 98.4 (91.3 to 100.0) |
| GDS for male participants, Month 6 | 100 (39.8 to 100.0) |
| PHD for female participants, Month 6 | 91.9 (82.2 to 97.3) |
| PHD for male participants, Month 6 | 100 (39.8 to 100.0) |
| BDS for female participants, Month 12 | 93.5 (84.3 to 98.2) |
| GDS for male participants, Month 12 | 100 (39.8 to 100.0) |
| PHD for female participants, Month 12 | 87.1 (76.1 to 94.3) |
| PHD for male participants, Month 12 | 75.0 (19.4 to 99.4) |
Uterine length was determined by transabdominal ultrasound. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| Month 6 | 64.5 (51.3 to 76.3) |
| Month 12 | 64.5 (51.3 to 76.3) |
Testis volume was a clinical assessment with orchidometer. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.
| percentage of participants | All Participants |
|---|---|
| Month 6 | 75.0 (19.4 to 99.4) |
| Month 12 | 75.0 (19.4 to 99.4) |
BMI analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
| kilogram (kg)/meter square | All Participants |
|---|---|
| Month 6 | 0.282 ± 0.882 |
| Month 12 | 1.195 ± 1.196 |
Weight analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.
| kg | All Participants |
|---|---|
| Month 6 | 2.020 ± 1.927 |
| Month 12 | 5.146 ± 2.816 |
Blood samples were collected at specified timepoints.
| ng/mL | All Participants |
|---|---|
| Day 1, 4 hours post-injection | 41.8 ± 56.9 |
| Month 3 | 0.0434 ± 76.8 |
| Month 6, predose | 0.0251 ± 648.7 |
| Month 6, 4 hours post-injection | 24.7 ± 66.0 |
| Month 12 | 0.0223 ± 110.3 |
Collected over Treatment-emergent adverse events were reported from the first dose of study treatment (Day 1) up to a maximum of approximately 344 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/66 (0%) | 0/66 (0%) | 59/66 (89.4%) |
| Event | All Participants |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 31/66 |
| COVID-19Infections and infestations | 10/66 |
| PyrexiaGeneral disorders | 9/66 |
| Weight increasedInvestigations | 9/66 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/66 |
| OverweightMetabolism and nutrition disorders | 7/66 |
| Suspected COVID-19Infections and infestations | 4/66 |
| BronchitisInfections and infestations | 4/66 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 3/66 |
| Abdominal painGastrointestinal disorders | 3/66 |
The intention-to-treat (ITT) population consisted of all participants who received at least 1 dose of study intervention.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 7.5 ± 0.9 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 62 |
| Male | 4 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Chinese | 66 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
Access criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
Data sharing details ↗ · vivli.org
Ran from Aug 2021 to primary completion in Aug 2022, 12 months.
Results were first posted in May 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin